Description: The widespread adoption and success of the Pd1 Pdl1 Inhibitors Market are highly contingent upon accurate patient selection, which is facilitated by sophisticated biomarker testing. The reliance on assays to measure PD-L1 expression, Tumor Mutational Burden (TMB), and Microsatellite Instability (MSI) is essential for rationalizing treatment decisions, predicting response, and...